Mandate

VINGE ADVISES HEXATRONIC IN CONJUNCTION WITH RIGHTS ISSUE AND OVERSUBSCRIPTION OPTION

March 02, 2015

Vinge has advised Hexatronic Group AB (publ) listed on NASDAQ Stockholm First North in conjunction with a rights issue of approximately SEK 41 million with an oversubscription option of approximately SEK 10 million, which may be exercised if the rights issue is oversubscribed. One subscription right is provided for each share in Hexatronic and six subscription rights entitle the holder to subscribe for one new share. The subscription price amounts to SEK 9 per share. It is estimated that the rights issue prospectus will be published on or about 14 April 2015.

Vinge’s team consisted of responsible partner Anders Strid together with associates Frida Bäckegren, Daniel Lennartsson and corporate assistant Camilla Andersson.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026